• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管内皮生长因子过表达预示肝细胞癌患者预后不良。

VEGF Overexpression Predicts Poor Survival in Hepatocellular Carcinoma.

作者信息

Choi Sae Byeol, Han Hyung Joon, Kim Wan Bae, Song Tae Jin, Choi Sang Yong

机构信息

Department of Surgery, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.

Department of Surgery, Korea University Guro Hospital, 80, Guro-dong, Guro-gu, Seoul152-703, Korea, Tel: +82-2-2626-3076.

出版信息

Open Med (Wars). 2017 Dec 9;12:430-439. doi: 10.1515/med-2017-0061. eCollection 2017.

DOI:10.1515/med-2017-0061
PMID:29318189
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5757349/
Abstract

OBJECTIVE

The aim of this study was to investigate the clinicopathological and immunohistochemical (including VEGF, Akt, HSP70, and HSP20 expression) factors that affect the overall and disease-free survival of HCC patients following surgical resection.

METHODS

234 patients with HCC following surgical resection were enrolled. Clinicopathological and survival data were analyzed, and immunohistochemical staining was performed on tissue microarray sections using the anti-VEGF, anti-Akt, anti-HSP70, and anti-HSP27 antibodies.

RESULTS

The 3- and 5-year overall survival rates were 86.5 and 81.54%, respectively. Multivariate analysis revealed that VEGF expression (P = 0.017, HR = 2.573) and T stage (P < 0.001, HR = 4.953) were independent prognostic factors for overall survival. Immunohistochemical staining showed that the expression of Akt, HSP70, and HSP27 did not affect the overall survival rate. The 3- and 5-year disease-free survival rates were 58.2 and 49.4%, respectively. Compared to the VEGF(-)/(+) group, the VEGF(++)/(+++) group demonstrated significantly higher proportion of patients with AFP levels > 400 ng/mL, capsule invasion, and microvascular invasion.

CONCLUSION

VEGF overexpression was associated with capsule invasion, microvascular invasion, and a poor overall survival rate.

摘要

目的

本研究旨在调查影响肝癌患者手术切除后总生存期和无病生存期的临床病理及免疫组化(包括VEGF、Akt、HSP70和HSP20表达)因素。

方法

纳入234例手术切除后的肝癌患者。分析临床病理和生存数据,并使用抗VEGF、抗Akt、抗HSP70和抗HSP27抗体对组织芯片切片进行免疫组化染色。

结果

3年和5年总生存率分别为86.5%和81.54%。多因素分析显示,VEGF表达(P = 0.017,HR = 2.573)和T分期(P < 0.001,HR = 4.953)是总生存期的独立预后因素。免疫组化染色显示,Akt、HSP70和HSP27的表达不影响总生存率。3年和5年无病生存率分别为58.2%和49.4%。与VEGF(-)/(+)组相比,VEGF(++)/(+++)组中AFP水平>400 ng/mL、包膜侵犯和微血管侵犯的患者比例显著更高。

结论

VEGF过表达与包膜侵犯、微血管侵犯及较差的总生存率相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1efc/5757349/d961f359705c/med-12-430-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1efc/5757349/1c8e6f29160e/med-12-430-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1efc/5757349/6e6c5fda8e9d/med-12-430-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1efc/5757349/d961f359705c/med-12-430-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1efc/5757349/1c8e6f29160e/med-12-430-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1efc/5757349/6e6c5fda8e9d/med-12-430-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1efc/5757349/d961f359705c/med-12-430-g003.jpg

相似文献

1
VEGF Overexpression Predicts Poor Survival in Hepatocellular Carcinoma.血管内皮生长因子过表达预示肝细胞癌患者预后不良。
Open Med (Wars). 2017 Dec 9;12:430-439. doi: 10.1515/med-2017-0061. eCollection 2017.
2
Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.神经胶质抗原2在肝细胞癌中的过表达预示预后不良。
World J Gastroenterol. 2015 Jun 7;21(21):6649-59. doi: 10.3748/wjg.v21.i21.6649.
3
High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation.蛋白磷酸酶2调节亚基B''α的高表达预示着肝细胞癌患者肝移植后的不良预后。
World J Gastrointest Oncol. 2021 Jul 15;13(7):716-731. doi: 10.4251/wjgo.v13.i7.716.
4
P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.P53免疫组化评分:肝细胞癌切除术后患者的独立预后标志物
World J Gastroenterol. 2002 Jun;8(3):459-63. doi: 10.3748/wjg.v8.i3.459.
5
[Expression of vascular endothelial growth factor (VEGF) family members and prognosis after hepatic resection in HBV-related hepatocellular carcinoma].[血管内皮生长因子(VEGF)家族成员表达与乙肝相关肝细胞癌肝切除术后预后]
Korean J Hepatol. 2008 Jun;14(2):185-96. doi: 10.3350/kjhep.2008.14.2.185.
6
Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma.CD105表达与肝细胞癌术后复发及转移的相关性
BMC Cancer. 2006 May 2;6:110. doi: 10.1186/1471-2407-6-110.
7
[Comparative analysis of anatomic and non-anatomic hepatectomy for single small hepatocellular carcinoma with microvascular invasion].[单发性小肝细胞癌伴微血管侵犯的解剖性与非解剖性肝切除术的对比分析]
Zhonghua Yi Xue Za Zhi. 2018 Jun 26;98(24):1937-1940. doi: 10.3760/cma.j.issn.0376-2491.2018.24.009.
8
Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy.术前血清甲胎蛋白(AFP)水平与肝癌(HCC)肝切除术后预后的相关性分析。
World J Surg Oncol. 2013 Aug 27;11:212. doi: 10.1186/1477-7819-11-212.
9
Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.术后辅助经导管动脉化疗栓塞治疗伴微血管侵犯的肝细胞癌患者的疗效。
World J Gastroenterol. 2017 Nov 7;23(41):7415-7424. doi: 10.3748/wjg.v23.i41.7415.
10
Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma.p57 表达缺失和 RhoA 过表达与肝癌患者的不良预后相关。
Oncol Rep. 2013 Oct;30(4):1707-14. doi: 10.3892/or.2013.2608. Epub 2013 Jul 9.

引用本文的文献

1
Prognostic Correlation of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor with Radiological Tumor Size in Pediatric Nephroblastoma and Neuroblastoma: A Prospective Study.小儿肾母细胞瘤和神经母细胞瘤中碱性成纤维细胞生长因子及血管内皮生长因子与肿瘤放射学大小的预后相关性:一项前瞻性研究
J Indian Assoc Pediatr Surg. 2025 Jan-Feb;30(1):36-40. doi: 10.4103/jiaps.jiaps_153_24. Epub 2025 Jan 2.
2
Angiopoietin-2 and the Vascular Endothelial Growth Factor Promote Migration and Invasion in Hepatocellular Carcinoma- and Intrahepatic Cholangiocarcinoma-Derived Spheroids.血管生成素-2与血管内皮生长因子促进肝癌和肝内胆管癌来源的球体迁移和侵袭。
Biomedicines. 2023 Dec 30;12(1):87. doi: 10.3390/biomedicines12010087.
3

本文引用的文献

1
Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.索拉非尼治疗伴有肝外转移的晚期肝细胞癌:一项前瞻性多中心队列研究。
Cancer Med. 2015 Dec;4(12):1836-43. doi: 10.1002/cam4.548. Epub 2015 Oct 16.
2
Microvascular invasion patterns affect survival in hepatocellular carcinoma patients after second hepatectomy.微血管侵犯模式影响肝细胞癌患者二次肝切除术后的生存情况。
J Surg Res. 2016 Jan;200(1):82-90. doi: 10.1016/j.jss.2015.06.069. Epub 2015 Jul 9.
3
Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways.
Novel -Arylmethyl-aniline/chalcone hybrids as potential VEGFR inhibitors: synthesis, biological evaluations, and molecular dynamic simulations.
新型芳基甲基苯胺/查尔酮杂合体作为潜在的 VEGFR 抑制剂:合成、生物评价和分子动力学模拟。
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2278022. doi: 10.1080/14756366.2023.2278022. Epub 2023 Nov 20.
4
Serum resistin and the risk for hepatocellular carcinoma in diabetic patients.血清抵抗素与糖尿病患者肝细胞癌的风险。
World J Gastroenterol. 2023 Jul 21;29(27):4271-4288. doi: 10.3748/wjg.v29.i27.4271.
5
Saikosaponin b2 inhibits tumor angiogenesis in liver cancer via down‑regulation of VEGF/ERK/HIF‑1α signaling.柴胡皂甙 b2 通过下调 VEGR/ERK/HIF-1α 信号通路抑制肝癌血管生成。
Oncol Rep. 2023 Jul;50(1). doi: 10.3892/or.2023.8573. Epub 2023 May 26.
6
Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review.肝细胞癌病因的预后评分与生存率:综述
J Clin Med Res. 2023 Apr;15(4):200-207. doi: 10.14740/jocmr4902. Epub 2023 Apr 28.
7
Prognostic value of SAT volume and density for predicting the outcome of patients with unresectable HCC treated with lenvatinib plus anti-PD-1 antibodies.SAT体积和密度对预测接受乐伐替尼联合抗PD-1抗体治疗的不可切除性肝癌患者预后的价值
Am J Cancer Res. 2023 Mar 15;13(3):912-921. eCollection 2023.
8
Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma.不可切除肝细胞癌的潜在分子靶向治疗。
Curr Oncol. 2023 Jan 18;30(2):1363-1380. doi: 10.3390/curroncol30020105.
9
Arterial instillation of rapamycin in treatment of rabbit hepatic xenograft tumors and its effects on VEGF, iNOS, HIF-1α, Bcl-2, Bax expression and microvessel density.经肝动脉灌注雷帕霉素治疗兔肝异种移植瘤及其对 VEGF、iNOS、HIF-1α、Bcl-2、Bax 表达和微血管密度的影响。
Sci Prog. 2021 Jul-Sep;104(3):368504211026417. doi: 10.1177/00368504211026417.
10
Serum vascular endothelial growth factor as a tumor marker for hepatocellular carcinoma in hepatitis C virus-related cirrhotic patients.血清血管内皮生长因子作为丙型肝炎病毒相关性肝硬化患者肝细胞癌的肿瘤标志物
World J Gastrointest Oncol. 2021 Jun 15;13(6):600-611. doi: 10.4251/wjgo.v13.i6.600.
苦参碱衍生物WM130通过抑制EGFR/ERK/MMP-2和PTEN/AKT信号通路来抑制肝细胞癌。
Cancer Lett. 2015 Nov 1;368(1):126-134. doi: 10.1016/j.canlet.2015.07.035. Epub 2015 Aug 7.
4
Postoperative complications are predictive of poor prognosis in hepatocellular carcinoma.术后并发症可预测肝细胞癌的预后不良。
J Surg Res. 2015 Dec;199(2):470-7. doi: 10.1016/j.jss.2015.06.012. Epub 2015 Jun 11.
5
Recurrent hepatocellular carcinoma: a Western strategy that emphasizes the impact of pathologic profile of the first resection.复发性肝细胞癌:一种强调首次切除病理特征影响的西方策略。
Surgery. 2015 Mar;157(3):454-62. doi: 10.1016/j.surg.2014.10.011. Epub 2014 Nov 6.
6
MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways.MicroRNA-21 抑制 PTEN 和 hSulf-1 的表达,并通过 AKT/ERK 通路促进肝癌进展。
Cancer Lett. 2013 Sep 1;337(2):226-36. doi: 10.1016/j.canlet.2013.05.007. Epub 2013 May 14.
7
Preoperative predictors of microvascular invasion in multinodular hepatocellular carcinoma.多结节性肝细胞癌微血管侵犯的术前预测因子。
Eur J Surg Oncol. 2013 Aug;39(8):858-64. doi: 10.1016/j.ejso.2013.04.003. Epub 2013 May 11.
8
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.联合靶向 AKT 和 mTOR 可协同抑制肝癌细胞的增殖。
Mol Cancer. 2012 Nov 20;11:85. doi: 10.1186/1476-4598-11-85.
9
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南:肝细胞癌的管理
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
10
Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma.根治性切除术后辅助肝动脉灌注化疗氟尿嘧啶和顺铂治疗肝细胞癌。
Oncology. 2011;81(3-4):184-91. doi: 10.1159/000333827. Epub 2011 Nov 8.